克洛皮多格雷尔耐药性及其相关性:当前的概念
Akshyaya Pradhan1, Monika Bhandari1, Pravesh Vishwakarma1
1Department of Cardiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Journal of family medicine and primary care
|July 19, 2024
概括
在CYP2C19的遗传变异降低了克洛皮戈格勒的有效性,增加了支架血栓形成和心血管事件的风险. 通过CYP2C19的基因定型,可以确定克洛皮戈格雷尔耐药性的患者,指导替代抗血小板疗法.
科学领域:
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
- 临床化学 临床化学
背景情况:
- 克洛皮多格雷尔是一种P2Y12受体抑制剂,是双抗血小板治疗的基石.
- 它充当前药物,需要通过细胞染色体P450 2C19 (CYP2C19) 通过肝脏代谢转化为活性形式.
- 克洛皮戈格雷尔的功效降低与CYP2C19基因中的遗传多态性有关.
研究的目的:
- 为了呈现一种冠状动脉支架血栓的病例,该病例归因于克洛皮戈格雷尔耐药性.
- 审查有关克洛皮戈格雷尔耐药性及其临床影响的文献.
- 讨论诊断方法,治疗策略和管理克洛皮戈格雷尔耐药性的未来方向.
主要方法:
- 案例报告的呈现方式.
- 关于克洛皮戈格雷尔耐药性和CYP2C19多态性的综合文献综述.
- 分析临床试验数据和当前治疗指南.
主要成果:
- CYP2C19遗传变异 (*2, *3, *4, *5) 导致活性代谢物形成减少,损害了血小板聚合抑制.
- 这种降低的抗血小板作用与支架血栓形成的发病率增加和不良心血管事件有关.
- 本案例强调了CYP2C19基因型与克洛皮戈格雷尔耐药性诱导的支架血栓形成之间的直接联系.
结论:
- 鉴定CYP2C19基因型对于识别克洛皮戈格雷尔耐药性至关重要.
- 根据遗传特征量身定制抗血小板疗法可以减轻支架血栓形成和循环心血管事件的风险.
- 需要进一步的研究和指导方针更新,以优化P2Y12抑制剂在不同患者群体中的使用.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
510
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
510
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
668
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
668
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125


